mAbs Inhibit Human RAGE by Blocking Its Binding to Heparan Sulfate
Monoclonal antibodies that block heparan sulfate binding to human RAGE, preventing its activation in disease states to serve as a therapeutic treatment.
Background:
Receptor for Advanced Glycation End products (RAGE), a widely expressed inflammatory receptor for disease states such as atherosclerosis, cancer, Alzheimer disease, drug-induced liver...
Published: 3/8/2024
|
Inventor(s): Ding Xu, Chih Yean Ong, Miaomiao Li
Keywords(s): Featured, Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Antibodies, Technology Classifications > Therapeutics and Vaccines
|
Compositions and Methods for Increased Circulation Half-Life
Single domain antibody composition that enable half-life extension and increased blood:tissue ratios.
Background:
While strategies such as PEGylation (PEG, polyethylene glycol), albumin binding, and Fc-fusion have been employed to extend the half-life of biological and pharmaceutical agents, there remains a need for additional strategies that not...
Published: 2/2/2024
|
Inventor(s): Brandon Bordeau, Joseph Balthasar, Toan Nguyen
Keywords(s): Featured, Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Antibodies, Technology Classifications > Therapeutics and Vaccines
|
Antiproliferative Betti Bases and Prodrugs Thereof
Betti base drugs and prodrugs optimized to enhance their antiproliferative activity through inhibition of MDM2, MDMX, p53, E3 ligase and FTH1.
Background:
Betti bases are a family of small organic molecules composed of phenolic or hydroxyarl benzylic amine derivatives. These molecules have established antiproliferative effects on various cancer cell...
Published: 2/2/2024
|
Inventor(s): Sherry Chemler, Xinjiang Wang, Samuel Galster, Rati Lama
Keywords(s): Featured, Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Biomedical Science and Engineering, Technology Classifications > Healthcare, Technology Classifications > Therapeutics and Vaccines
|
Antimicrobial Compositions and Combination Therapies
Compositions and methods to combat drug-resistant Pseudomonas aeruginosa infections.
Background:
Antibiotic resistance is an urgent and growing health threat. Pseudomonas aeruginosa is known to cause a variety of infections in both immunocompetent and immunocompromised individuals, but especially the latter. It utilizes both intrinsic and acquired...
Published: 2/2/2024
|
Inventor(s): Mark Sutton, Brian Tsuji, Anthony Berdis
Keywords(s): Featured, Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Therapeutics and Vaccines
|
Benzodiazepinone-derived Inhibitors of EGFR and HER2
A class of benzodiazepinone-derived molecules, inhibitors of both triple mutant EGFR and HER2, for cancer therapeutics or biochemical research tools.
Background:
Inhibition of epithelial growth factor receptor (EGFR) as a non-small cell lung cancer (NSCLC) therapeutic is not a new concept, but 75% of patients die within five years of diagnosis. As...
Published: 2/7/2024
|
Inventor(s): David Heppner, Stefan Laufer, Florian Wittlinger, Blessing Ogboo, Calvin Pham, Alexander Rasch
Keywords(s): Featured, Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Materials and Chemicals
|
Targeted delivery of matrix-modulating enzymes
For enhanced monoclonal antibody uptake and distribution in solid tumors.
Background:
Penetration of anti-tumor therapies is often limited by the tumor microenvironment, which can include a high density of extracellular matrix as well as elevated interstitial fluid pressure, both of which create a barrier to distribution. It is well established...
Published: 2/2/2024
|
Inventor(s): Joseph Balthasar, Brandon Bordeau
Keywords(s): Technologies
Category(s): Technology Classifications, Technology Classifications > Antibodies, Technology Classifications > Therapeutics and Vaccines, Campus > University at Buffalo
|
Tool for Predicting Clinical Immunogenicity
An in vitro tool for predicting clinical immunogenicity of subcutaneously administered therapeutic proteins.
Background:
Immunogenicity, the propensity of a product to elicit an immune response to itself or related structures, has the potential to reduce or eliminate the therapeutic benefit it is intended to provide, and may even lead to adverse...
Published: 2/2/2024
|
Inventor(s): Sathy Balu-Iyer, Nicole Jarvi
Keywords(s): Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Research Tools and Reagents, Technology Classifications > Therapeutics and Vaccines
|
Bioengineering Platform for Delivery of Peptides into Cells
A platform bioengineering approach, which combines orthogonal protein crosslinking with supercharging protein surfaces, to design and develop cell-penetrating monobodies.
Background:
Intracellular targets, including a number of high-profile oncology-related ones, remain "undruggable". While small molecules are generally able to cross biological...
Published: 2/2/2024
|
Inventor(s): Qing Lin
Keywords(s): Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Therapeutics and Vaccines
|
Shear-Thinning Hydrogels
Shear-thinning, biocompatible hydrogels that are useful for cell therapy and which hold promise for 3D printing of functional tissue constructs.
Background:
While hydrogels hold great promise in applications such as drug delivery and tissue engineering, their fast gelation kinetics restrict their use in injectable applications such as the delivery...
Published: 2/7/2024
|
Inventor(s): Stelios Andreadis, Mohamed Mohamed
Keywords(s): Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Biomedical Science and Engineering, Technology Classifications > Therapeutics and Vaccines
|
Targeted Delivery of Dopamine Transporter Genes to Dopamine Neurons (MTA)
An adeno-associated virus vector delivering genes controlled by a tyrosine hydroxylase promoter to dopaminergic neurons. Adeno-associated viruses (AAVs) were created to specifically deliver genes to dopaminergic neurons. The proof-of-principle experiment delivered DAt under the control of a tyrosine hydroxylase promoter in a mouse model of dopamine...
Published: 4/5/2023
|
Inventor(s): Caroline Bass, Patrick Fuller, Raul Gainetdinov
Keywords(s): Technologies
Category(s): Technology Classifications > Therapeutics and Vaccines, Campus > University at Buffalo
|